FEATURE
FEATURE
Precision medicine
collaboration to increase
options for cancer patients
On May 20, Baylor Research Institute
(BRI) at Dallas and the Translational
Genomics Research Institute (TGen) in
Phoenix, announced an agreement that will
focus on accelerating early detection and
treatments for patients with a broad range
of cancers. Aligning the best science of both
institutions will lead to new clinical trials
and access to technology to drive the development of new therapies – bridging the gap
from bench to bedside across Baylor Scott
& White Health’s 49 hospitals throughout
Texas.
Robert Pryor, M.D., president, chief
operating officer and chief medical officer,
Baylor Scott & White Health, is excited
about the collaboration saying, “We will
combine TGen’s strengths in genomics and
proteomics with BRI’s strengths in metabolomics and immune-based approaches,
initially focusing on genomic – or molecular – and translational research for
oncology.”
Daniel Von Hoff, M.D., TGen’s distinguished professor and physician-in-chief
and senior research advisor for the
Pancreatic Cancer Research and Treatment
Center at Baylor University Medical Center
at Dallas, discussed the potential of the collaboration at the May Baylor Health Care
System Foundation board meeting.
Dr. Von Hoff explained the joint effort
will concentrate on three significant
research areas: women’s cancer, including
breast and